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Despite the success of cisplatin in the treatment of individuals afflicted with advanced 
testicular cancer and other types of cancer, it has a broad spectrum of side-effects like  
nephrotoxicity and neurotoxicity. There is a need for new platinum complexes that are 
able to broaden the biological activity spectrum and eliminate the multifactorial drug 
resistance. Surprisingly, cisplatin based DNA-Pt adducts and its analogues are almost 
identical, leading to similar patterns of tumor sensitivity and susceptibility to resistance. 
Platinum(II) complexes with sulfur-containing ligands have shown high efficacy for 
some human cell line comparable to that of the cisplatin. In this study, we synthesized a 
series of new platinum complexes with some thione ligands (Figure 1) and characterized 










Pt solid NMR spectroscopy) and single-
crystal X-ray crystallography. The coordination site was discussed in the light of the 
various data obtained. Two of the complexes, [Pt(MeImt)4]Cl2 (1B) and [Pt(Diaz)4]Cl2 
(9B), were characterized based on their X-ray crystallography and showed that the 
platinum atom is connected to four sulfur atoms; each belonging to thione ligand in a 





  ملخص الرسالة
ABSTRACT (ARABIC) 
 أحمد زين العابدين عبدهللا مصطفى: لاالسم الكام
 




 3102مايو : تاريخ الدرجة العلمية
 
 الخصية بسرطان المصابين المرضى من اآلالف عالج في (cisplatin) سيسبالتين عقار نجاح من الرغم على
 والسمية الكلوي الفشل مثل الجانبية لديه مجموعة واسعة من اآلثارإال أن  السرطان، من أخرى وأنواع المتطورة
 النشاط نطاق توسيع على قادرة جديدة بالتين معقدات لتحضير ماسة حاجة هناك .وغيرهما (األعصاب تلف( العصبية
 سيسبالتينأن نواتج االضافة المتكونة من تفاعل  المثير للدهشة. للعقاقير الخاليا مقاومة على والقضاء البيولوجي
قابلية  ماثلة من حساسية الورم وتكاد تكون متطابقة، مما يؤدي إلى أنماط م (DNA)النووي  مع الحمض ونظائره
فعالية على الكبريت  تحتوي التي تتكون من مترابطات( II)البالتين  لقد أظهرت معقدات .للمقاومة الخاليا السرطانية
 معقداتسلسلة من  قمنا بتخليقفي هذه الدراسة،  .السيسبالتينبمقارنة  الخاليا البشرية وطية بالنسبة لبعض خطعال
 Elemental)رالعناص تحليل اتتقني بواسطةووصفناها  (0الشكل ) نثيوال مترابطاتجديدة مع بعض الالبالتين 
Analysis) ، مطيافية األشعة تحت الحمراء (Infrared spectroscopy)،  مطيافية رامان(Raman 
spectroscopy) ،ي المغناطيس النووي الرنين(NMR)،   األشعة السينية البلوراتو (X-ray 
crystallography.) تصلت المترابطات جميع أن ووجد عليها المتحصل النتائح على إعتمادا الترابط موقع مناقشة تم 
 السينية األشعة طريق عن المعقدات هذه من إثنان دراسة تم أيضا .فيها الكبريت ذرة طريق عن المركزية الذرة مع
 أربع مع تربتط المركزية البالتين ذرة أن ووجد  (Pt(Diaz)4]Cl2 (9B]و (Pt(MeImt)4]Cl2 (1B] للبلورات




1 CHAPTER 1 
INTRODUCTION 
Since the discovery of platinum-based drug, cispatin [1] and finding its ability in the 
treatment of malignant tumors of the urogenital tract and some other types of cancers [2], 
platinum metal became one of the most important players in the field of bioinorganic 
chemistry.  Despite the success of cisplatin in the treatment of thousands of individuals 
afflicted with advanced testicular cancer [3], ovarian carcinoma [4], head and neck 
cancer, melanoma, and lymphomas cancers [5], its clinical use diminished by its side 
effects such as nephrotoxicity [6] and gastrointestinal effects [7], and also by the 
resistance of cancer cells to the drug.  Thousands of platinum complexes have been 
synthesized in order to overcome these side effects.  It has been found that all 
platinum(II) complexes share one common structure which is cis coordination of two 
amino groups (bearing at least NH) and two leaving groups such as chloride, citrate or 
oxalate [8, 9], they bind to the DNA through 1,2-intrastrand cross-links, between N7 
atoms of two adjacent Guanine (G) with platinum(II) ion [10], therefore, they cause in 
most cases same side effects.   
The need for generation of new platinum complexes that are able to broaden the 
biological activity spectrum and eliminate the multifactorial drug resistance resulted in 
the formation of structurally novel platinum complexes containing biologically active 




the one of  cisplatin.  Studies found that cisplatin-like drugs can introduce nephrotoxicity 
due to their reaction with sulfur-containing amino acids of the proteins; cysteine and 
methionine [10].  Platinum(II) complexes with sulfur-containing ligands, like dimethyl 
sulfoxide, dimethyl sulfide, xanthate  and thiosemicarbazones [11-13], have represented 
high efficacy for some human cell line.  Thiourea and its derivatives, as sulfur-containing 
ligands, may give better results if they coordinate with the platinum(II) ion.  They have 
been used for a long time as antifungal agents [14], rescue agents against nephritic side 
effects during cispalin administration [10], and as  inhibitors of HIV-1 and HIV-2 reverse 
transcriptases [15].  Platinum(II) complexes with thiourea ligands demonstrated that they 
can bind to the DNA in a different mechanism than that of cisplatin and showed excellent 
cytotoxicity against ovarian and leukemia cancer cell lines [16, 17].  This success of 
thiourea and its derivatives in cancer treatment encouraged us to synthesize new platinum 
complexes with some thiourea derivatives and characterize them using different 
analytical techniques. 
1.1 Research problem 
Cisplatin-like drugs can introduce nephrotoxicity due to their reaction with sulfur-
containing nucleophile glutathione (γ-L-glutamyl-L-cysteinylglycine, GSH) [18].  In 
recent years, research has focused on the study of  platinum complexes with sulfur- 
containing ligands.  Those based on thiourea have long been known and their importance, 
at first, was not because of their biological activities.  For instance, the 
tetra(thiourea)platinum(II) chloride’s structure was determined in order to study the 




with platinum(II) complexes were also synthesized and crystallographically characterized 
because of the interest in new platinum anticancer complexes with heterocyclic ligands 
containing sulfur and nitrogen atom.  As an example Tetrakis(1-methyl-2(3H)-
imidazolinethione)platinum(II) chloride and nitrate, were synthesized in 1982 [20] and in 
2004 [21], respectively. 
 This success of platinum complexes with S-donor ligands in cancer treatment 
encouraged us to prepare a series of thione-containing platinum(II) complexes.   
1.2 Aims of the study  
i. To study the reaction of K2PtCl4 with a series of thione ligands (Figure 1) in 1:2 & 
1:4 ratios to synthesize complexes with general formulas [PtL2Cl2] and [PtL4]Cl2, 
respectively. 
ii. To fully characterize the synthesized complexes by elemental analysis, Infrared 










































            (1-8)               (9-10)                          (11) 
1. R = CH3, R
/
 = H; N-methylimidazolidine-2-thione (MeImt) 
2. R = C2H5, R
/
 = H; N-ethylimidazolidine-2-thione (EtImt) 
3. R = C3H7, R
/
 = H; N-propylimidazolidine-2-thione (PrImt) 
4. R = i-C3H7, R
/
 = H; N-(i-propyl)imidazolidine-2-thione (i-PrImt) 
5. R = R/ = CH3; N,N
/
-dimethylimidazolidine-2-thione (Me2Imt) 
6. R = R/ = C2H5; N,N
/
-diethylimidazolidine-2-thione (Et2Imt) 
7. R = R/ = i-C3H7; N,N
/
-di-(i-propyl)imidazolidine-2-thione (i-Pr2Imt) 
8. R = C2H5, R
/
 = CH3; N-ethyl-N
/
-methylimidazolidine-2-thione (EtMeImt) 
9. R = H; 1,3-Diazinane-2-thione (Diaz) 
10. R = C2H5; N-ethyl-1,3-Diazinane-2-thione (EtDiaz) 
11. 1,3-Diazipane-2-thione (Diap) 










2 CHAPTER 2 
LITERATURE REVIEW 
2.1 Metals in Medicine – A Historical Background 
The introduction of inorganic metals in medicine started thousands of years ago; since the 
time of the ancient Egyptians.  Alums and Copper sulfate have been used due to their 
effects on the concoction produced in the process of potion preparation.  Mercury was 
used recently, for the treatment of syphilis during the European epidemic between the 
15th and 16th centuries [22].  The arsenic compound Salvarsan, has been introduced by 
Erlich in 1909 as a cure for syphilis too [23].  In the middle of the last century, two 
elements have changed the course of medicine by their great prominence in the medicinal 
use of metal compounds; one of these was the technetium, and the other was the platinum 
metal.  The man-made element technetium, was discovered by C.  Perrier and E.  Serge in 
1937, by neutron capture in molybdenum ores.  During the latter part of the past century, 
technetium gained much interest because of its important contribution to the diagnostic 
medicine [24].  The use of platinum complexes in medicine, as an anticancer drug, started 
at the time of the great serendipitous discovery made by physicist-turned-biophysicist 
Barnett Rosenberg at Michigan State University, East Lansing, United States.  He was 
trying to find whether there is a contribution of magnetic or electronic dipole fields on 
cell division by applying electromagnetic radiation on mammalian and bacterial cells.  




Escherichia coli.  After applying the electromagnetic field, they were strange growth of 
the bacteria length; which reached up to 300 times the normal.  This phenomenon could 
not be attributed to the effect of the applied field.  Investigation studies found that the 
products of electrolysis process at the platinum electrodes (cisplatin, neutral cis- 
[Pt(NH3)2Cl2], and its platinum(IV) analogue, cis-[Pt(NH3)2Cl4]), are the causing 
molecules of these biological effects [1].  At present, cisplatin is considered to be one of 
the most extensively used drugs against cancer.  This is due to its activity against bladder, 
cervical, ovarian, head and neck, testicular, and small-cell and non-small cell lung 
cancers [25, 26].  In spite of the above mentioned advantages, cisplatin is ineffective in 
other cancers e.g.  leukemia, gastrointestinal, and renal cancers [27]. 
2.2 Cancer and Cancer Chemotherapy 
The term cancer is used for a collection of diseases which are known to cause failure of 
the division, growth and spreads all over the body and lead to a malignant tumor that 
attacks and damages the neighboring tissues [28].  Also it may extend to other parts of 
the body through the metastasis process, which is responsible for about 90% of cancer 
deaths [28, 29].  Cancer is also responsible for more than 13% of all deaths worldwide 
[28, 30], and it remains a difficult disease to treat.  The challenge now is to get a drug 
which capable of eradicating this dread disease permanently. 
The abnormality of the genetic material is the normal cause of cancer for  the affected 
cells.  This happens in a  multistep process that is called tumorigenesis, which is 
responsible for producing or tending to produce tumors.  It may include large or small-




structure.  In all cases, these mutations can induce dramatic effects on general nuclear 
activities, such as DNA repair and DNA replication, or on  special activities such as the 
expression of key growth regulatory genes [31].  Cancer is not just a cell disease, it is 
also a tissue disease that interrupts the normal relationships between epithelial cells and 
their underlying stromal cells [32].  Cancer can be treated based on radiotherapy, surgery, 
and with systemic chemotherapy.  Unfortunately, these treatments do not totally cure the 
patients, they may not give benefit at all, or just a prolonged survival [22].  The aim of 
these chemotherapeutic drugs is to kill malignant tumor cells through inhibiting their 
cellular division, but there are just a small number of subgroups that can benefit from the 
effective targeted therapies [33].  It is clear that the development of a cancer 
chemotherapy is a very difficult task to achieve [34].  One of the most difficult problems 
associated with cancer chemotherapy is the nonspecific toxicity due to the spread out of 
the drug throughout the body, which requites large dose of the pharmaceuticals to achieve 
high concentrations at a local tumor [35].  Drug resistance also represents another 
problem in cancer chemotherapy (see also Section 2.4.3), which could be defined as the 
ability of cancer cells to resist different drugs [36].  There are different ways by which 
cancer cells can evade the chemotherapy.  This resistance exists against all kinds of 
drugs, even the newly applied ones.  Therefore, it’s necessary to circumvent drug 
resistance to improve the chemotherapy [37].  Finally, the major problem that is facing 
the development of a new anticancer chemotherapy is the big gap between the promising 
findings in preclinical in vivo and in vitro models and the real clinical results obtained in 




2.3  Natural Products in Cancer Chemotherapy 
Natural products and their derivatives play a highly significant role in the discovery and 
development of the cytotoxic anticancer agents.  Around half of the currently used 
anticancer drugs are originally natural products, it has also been found that these natural 
products and their derivatives represent about 60% of the newly introduced chemical in 
this field in the 1981–2002 period [38].  Microorganisms, marine organisms, and plants 
are the main sources of anticancer agents in cancer chemotherapy [39].  Actinomycetes 
are categorized as microorganisms that produce natural products with antimicrobial and 
anti-tumor properties.  Figure 1 shows the structures of some microbial anti-tumor agents.  
The microbial product (actinomycin D) has shown 90% survival rate against stage I or 
stage II Wilm’s tumor [40].  Bleomycin is used for testis and Hodgkin’s lymphoma 
tumors and squamous cell carcinomas.  It is originally produced by Streptoalloteichus 
hindustanus.  A bleomycin derivative, Blenoxane, is used against the head, neck and 
testicles tumors, skin and lymphomas carcinomas [41], and the pingyangmycin derivative 
has also been used in china since 1978 in cancer therapy [42].  A dramatic example that 
demonstrates the efficacy of the natural products is that used against metastatic testicular 
cancer, which lifted the rate of treatment from 5% in 1974 to 90% in 2002; due to the use 
of a triple combination of the plant compound etoposide, the microbial product 
bleomycin and the synthetic agent cisplatin [43].  Camptothecin is a monoterpene indole 
alkaloid used against colon cancer, it has remarkable activity against lung, uterine, and 
ovarian cancer.  Camptothecin produced by certain angiosperm plants, and by the 




produces camptothecin with a yield higher than that of the chemical synthesis.  Fungal 
fermentation gives promising solutions for pharmaceutical production [44, 45].   
 




2.4 Cisplatin, cis-diamminedichloroplatinum(II) (CDDP) 
This anticancer drug has been synthesized 130 years before its biological activity was 
discovered by Italian chemist Michele Peyrone in 1844, and was known as Peyrone’s 
chloride [46].  Cisplatin was shown to cause marked tumor regression against the mice 
tumor, sarcoma-180 [47].  In 1971 the US National Cancer Institute (NCI) got the 
approval from the US president at that time, Richard M.  Nixon, to begin  testing the 
cytotoxicity of cisplatin against human cancer cell lines.  The US Food and Drug 
Administration (FDA) approved in 1978 the use of cisplatin for the first time in 
association with other drugs in the treatment of metastatic ovarian cancer and metastatic 
testicular cancer [25].  The clinical use of cisplatin is diminished by drug resistance 
which can be either acquired or intrinsic.  Many cancers, including ovarian cancer, that 
was initially treated with cisplatin gained resistant to it [25, 48].  Nephrotoxicity  is one 
of the  major toxicity limitations beside other side effects such as nausea and vomiting, 
myelotoxicity as well as peripheral neuropathy [6, 49].  Many attempts have been made 
in order to design new platinum drugs safer for patients, in particular, to remove or at 
least decrease the unpredictable and severe nephrotoxicity and/or to provide 
bioavailability for oral administration [50].   
2.4.1 Platinum and Palladium Chemistry 
The primary oxidation states of the platinum metal are II and IV, in special cases the I 
and III can be presented in cooperation with M−M bond, also it may be found in the 0 
oxidation state, where CO, PR3, and other π-acid ligands existed.  Mixed oxidation states 




in most of their complexes in square-planar geometry.  Particularly the form complexes 
of general formula MX2L2, where X  monodentate anion; L = donor ligand.  These 
complexes may exist as cis and trans isomers.  Platinum and Palladium (II)  commonly 
represent low affinity for hard ions such as O and F
−
, and bind preferably to heavier 




, alkenes and 
alkynes).  Although their complexes are usually similar, platinum complexes are more 
stable than their palladium analogues in both the kinetic and the thermodynamic sense.  
The kinetic inertness of platinum (II) complexes made them important in the field of 
coordination chemistry because of the ease of the study of the reaction mechanisms and 
the geometrical isomerization [51]. 
2.4.2 Cisplatin Mechanism of Action 
There is overwhelming evidence that cisplatin becomes activated intracellularly before it 
can reach its target of DNA through the aquation mechanism (one of the chlorines is 
replaced by water) followed by formation of DNA adducts (Figure 3).  Careful studies, 
conducted in vitro showed platinum binding to the N7 of the purine bases of DNA 
guanine (G), and to a lesser extent, adenine (A) to form different kind of  platinum- DNA 
adducts, such as GpG 1,2 intrastrand (60–65% of all adducts) through binding of 
platinum complex to two adjacent guanine (G) of the same DNA strand, or ApG 1,2 
intrastrand (20–25% of all adducts) through binding of platinum to two adjacent 
nucleobases; adenine (A) and guanine (G) of same DNA strand.  There are also less 
frequent adducts which arise through binding to different DNA strands [52].  These 






Figure 3.  Cisplatin Mechanism of Action 
 
2.4.3 Tumors Resistance to Cisplatin 
Scientists were happy after the initial promising data obtained with cisplatin, and with its 
analogue carboplatin, then attention shifted to study of how tumor resistance was made 
during courses of chemotherapy with these anticancer drugs, and why some other tumors 




behind the hypersensitivity of testicular cancer to cisplatin.  The studies concluded that 
they may be two reasons behind the above mentioned tumor resistance: first is the failure 
in delivering an adequate quantity of the platinum drug to the DNA target, the second one 
is the failure to reach cell death after the formation of platinum-DNA adducts [50]. 
2.4.3.1.Resistance Through Insufficient DNA Binding 
Over many years, it has been observed that, a resistance is acquired through the course of 
cisplatin administration in many tumor cells.  A reduction of platinum concentration 
accumulated in the cells occurs compared to that of the parental cells [54].  However, till 
now, the exact mechanism in which the anticancer drug gets into the cells is still unclear.  
The intake of cisplatin is affected by several elements [55], like pH, the concentration of 
the potassium and the sodium ions, the existence of reducing agents; and the way that the 
drug is transportsed either through hypothesized gated channels or passive diffusion 
(Figure 4).  The major plasma-membrane transporter, copper transporter-1 (CTR1), 
which has an essential role in copper homeostasis, was found to be involved in cisplatin 
influx, the loss of CTR1 has led to increase in drug resistance even high concentrations of 
cisplatin [56].  Also there is an evidence that the high concentration of sulfur-containing 
species, such as metallothioneins [57, 58], and glutathione [59, 60], which are affluent in 
the sulfur-containing amino acids, methionine and cysteine, will lead up to detoxification 





Figure 4.  Tumor Resistance to Cisplatin Mediated by Inadequate Levels of 
Platinum Reaching Target DNA 
 
2.4.3.2.Resistance mediated after DNA binding 
Acquired resistance to cisplatin could also occur after the formation of platinum–DNA 
adducts, through cellular survival either by removal or tolerance of DNA damage [61].  
The supersensitivity of testicular cancer to cisplatin was to be a result from DNA-repair 
deficiency.  By contrast, there are many types of cisplatin-resistant cell lines have been 
shown to have tumor drug resistance because of the increase in the DNA-repair capacity 
[62].   
2.4.4 Cisplatin Side Effects 
The anti-tumor agent, cisplatin, is extremely used for solid tumors treatment, but it 




ototoxicity, neuropathy, and nephrotoxicity; due to its lack of the selectivity for tumor 
cells.  Nephrotoxicity is the main effect that hampers the use of cisplatin in the 
therapeutic process [63-65].  Studies found that 25% of patients may develop reversible 
azotemia after receiving a single dose of cisplatin [66].  In addition, irreversible kidney 
failure also may occur at large doses, or with frequent cycles of treatment [67].  
Nephrotoxicity induced by a complex process involves severe cytotoxic effects on 
tubular epithelial cells, that reduce them via apoptosis, and necrosis, followed by 
fibroproliferative changes and inflammatory cell infiltration [68].  Cisplatin  partially 
inhibits the protein synthesis in the tubular epithelial cells, and also disrupts the cellular 
antioxidant defense system (i.e., glutathione, GSH), resulting in DNA damage and lipid 
peroxidation.  Glutathione, (GSH) could be administered to alter the nephrotoxicity 
induced by cisplatin [69], without affecting its antitumor activities [70].   
2.5 Platinum Complexes as Anticancer Agents 
Platinum compounds that are now excessively used in clinic represent a unique class of 
DNA damage [71].  It has been found that the only platinum complexes that possess cis 
geometry are able exhibit anticancer activity.  The most active platinum complex, 
cisplatin, (Figure 5, A), was found to block the cell growth, while its  trans isomer did 
not show such activity [71].  There are many platinum compounds that also inhibit the 
cell growth, these complexes generally bear at least one N-H group, that is needed 
because of its hydrogen-bond donor properties required  in the binding with the 
biological target, or in the final structure.  The general formula for the most known 




leaving group, such as chloride, citrate or oxalate and R = organic fragment [72].  The 
development of platinum anticancer complexes resulted in what so called the second-
generation platinum anticancer drug carboplatin [Pt(C6H6O4)(NH3)2], (Figure 5, B), 
which has less side effects than cisplatin and is more readily applied in combination 
therapy.  It has to be administered in a higher dosage because of its low reactivity.  This 
anticancer agent is generally used for ovarian cancer therapy [71].  The third-generation 
drugs,  oxaliplatin, (Figure 5, C), have been developed in order to overcome the 
spontaneous (intrinsic) drug resistance that may appear in particular tumors.  These 
platinum complexes do not follow the classical cis-diamine structure with two leaving 
groups.  Oxaliplatin is most effective in colon cancer therapy [73].  The Second-
generation anticancer drugs such as (cis-diammine(1,1-cyclobutanedicarboxylato) 
platinum(II)), carboplatin, and [PtCl2(dach)] (dach ) trans-1,2- cyclohexanediamine) end 
up at the same DNA adducts like that of the parent drug cisplatin and so they are not 
expected to overcome the  resistance of cells to the drug [74].   
 
Figure 5.  Chemical Structures of Platinum Compounds (A) Cisplatin, (B) 





The need for generating new platinum complexes which are able to broaden the 
biological activity spectrum and lead to eliminate the multifactorial drug resistance, 
resulted in the formation of structurally novel platinum complexes containing 
biologically active ligands that are supposed to interact with the DNA in non-cisplatin 
behavior.  Very careful investigation studies found that cisplatin-like drugs can introduce 
nephrotoxicity due to their reaction with sulfur-containing amino acids methionine and 
cysteine, because the platinum readily binds to sulfur [10].  The nephrotoxicity might be 
controlled by using rescue agents; usually sulfur-containing ligands these include 
thiourea, glutathione (GSH), sodium thiosulfate (STS), and Sodium 
Diethyldithiocarbamate (NaDDTC) [10, 75, 76].  Borch and Pleasants have suggested 
that nephrotoxicity might be a result of inactivation of specific enzymes due to binding 
with cisplatin through their sulfhyryl groups of cysteine residues and these rescue agents 
are able to restore the original structure of the enzymes by removing the platinum from 
their sulfur atoms, therefore reduce the nephrotoxicity [77].  Platinum(II) complexes with 
sulfur-containing ligands, such as dimethyl sulfoxide, dimethyl sulfide, xanthate and 
thiosemicarbazones have shown high efficacy for some human cell line comparable to 
that of the cisplatin [11-13].  Some platinum(II) complexes showed that they may induce 
apoptosis in a mechanism different than that of cisplatin and showed excellent 
cytotoxicity against leukemia and ovarian cancer cell lines [11, 17].  Thiourea and its 
derivatives, as a class of sulfur containing ligands, may give a better result if they 
coordinated with platinum(II) ion.  They have been used for a long time as antifungal 
agents [14], rescue agent against nephritic side effects during cispalin administration 




2.6 Imidazolidine-2-thione and its N-substituted derivatives 
1,3-imidazolidine-2-thiones and their derivatives are an interesting class of ligands due to 
their significant pharmaceutical benefits and their ambidentate nature [79].  Substituted 
Imidazolidine-2-thiones offer noticeable biological activity; for example, they have been 
reported to exhibit antimicrobial activity [80], antifungal activity , anti-HIV activity and 
in cancer treatment [81].  These ligands can coordinate to a metal through various 
chelating modes, by their sulfur or nitrogen atoms.  Also they may exist in a thiol-thione 
equilibrium [82].  Studies found that the latter one is the dominant form of the complexes 
in the solid state and in the most common solvents [82, 83].  The reactions of thione 
ligands with transition metals have been well studied.  Complexes of Cu(I), Ag(I), Pd(II) 
Au(I), Cd(II), and Hg(II) have been synthesized in recent years in order to find simple 










3 CHAPTER 3 
EXPERIMENTAL 
3.1 Materials and Measurements 
K2PtCl4 was purchased from Strem Chemicals, Inc.  The deuterated solvents were 
purchased from Sigma-Aldrich Chemical Co.  The thione ligands were prepared based on 
(Thorn et al., 1955 [91]) and (Maier et al., 1970 [92]) by the addition of the carbon 
disulfide to diamines in ether, the adduct was then refluxed at 100−110 °C for 2−3 hours 
and the clear yellow product was recrystallized from methanol.  All other solvents were 
obtained from Fluka Chemical Co. and used without further purification.  Elemental 
analysis for carbon, hydrogen, nitrogen and sulfur were performed on PerkinElmer 2400 
Series II CHNS/O Elemental Analyzer.  Infrared spectra were recorded in the range 
4000–400 cm
−1
 as KBr discs using Nicolet 6700 FT-IR Spectrometer.  The FT-Raman 
spectra of the platinum(II) complexes were obtained on NXR FT-Raman Module.  The 
samples were studied in the solid state, placed in NMR tubes.  A power of 500 mW was 




H NMR spectra were obtained 
on Jeol JNM-LA 500 NMR spectrometer operating at a frequency of 500.00 MHz.  
13
C 
NMR spectra were obtained at the frequency of 125.65 MHz with 
1
H broadband 
decoupling at 298 K.  The spectral conditions were: 32k data points, 0.967 s acquisition 
time, 1.00 or 30.00 s pulse delay and 45
o
 pulse angle. Solid state cross-polarization 








at ambient temperature on a Bruker 400 NMR spectrometer operating at a frequency of 
85.94 MHz.  Contact time of 3 ms was used with a proton pulse width of 4 s, with a 
recycle delay of 10 s.  Approximately 5000 FID’s were collected and transformed with a 
line broadening of 100 Hz.  Chemical shifts were referenced using an external sample of 
solid K2[PtCl6].  The sample was spun at 11 and 8 kHz at the magic angle to identify the 
center peak.  The CPMAS spectra containing spinning side-band manifolds were 
analyzed using a computer software WSOLIDS developed at Dalhousie and Turbingen 
universities, to yield the anisotropy and asymmetry parameters [93].  The spectrum 
obtained at 11 kHz is shown in (Figure 6) and the NMR parameters are as follows: 
isotropic chemical shift = -3500 ppm; anisotropy = 2196 ppm and asymmetry = 0.71. 
3.2 Preparation of complexes 
3.2.1 Synthesis of PtL2Cl2 complexes 
To a 10 cm
3
 aqueous solution of K2PtCl4 (0.415 g, 1.00 mmol) was added dropwise a 15 
cm
3
 of an aqueous solution of thione ligand (2.00 mmol), immediately, a precipitate 
formed which after stirring at room temperature for 15 minutes was filtered, washed with 
cold water, ethanol and ether, then dried under vacuum at 30 ºC overnight.  Thiones 
Et2Imt (6), i-Pr2Imt (7), EtMeImt (8) and EtDiaz (10) are slightly soluble in water, so 
they have been dissolved in a mixture of water and ethanol, and the reaction carried out 




3.2.2 Synthesis of [PtL4]Cl2 complexes 
For a hot aqueous solution (25 cm
3
)  of a thione ligand (2.00 mmol) was added a solution 
of K2PtCl4 (0.208 g, 0.500 mmol) in 3 cm
3 
of water, the mixture was refluxed for 4 hours, 
during which time a clear yellow solution formed in most complexes.  This was filtered 
whilst hot.  Yellow crystals of 1B, and 9B suitable for X-ray diffraction analyses were 
obtained by slow evaporation of the solvent.  Analytical data are summarized in Table 1. 
Table 1.  Elemental Analytical Data For The Platinum Complexes 
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180-182 Beige  91.2 










 Yellow 58.9 








154-155 Beige  98.9 










 Yellow 64.3 








150-107 Yellow 77.5 










 Yellow 89.3 








167-168 Brown 76.3 








145-146 Yellow 92.5 








185-186 Yellow 78.1 




















183-185 Brown 40.5 








150-151 Orange 42.0 








213-215 Yellow 68.3 








250-252 Yellow 97.3 








60-62 Orange 63.1 








113-114 Yellow 52.5 








200-202 Yellow 97.0 










 Yellow 35.3 
a
 Decomposition point. 
 
 
3.3 X-ray Crystallography 
X-ray diffraction data were recorded on a Bruker-Axs Smart Apex system equipped with 
a graphite monochromatized Mo K radiation ( = 0.71073 Å).  The data were collected 
using SMART [94].  The data integration was performed using SAINT [95].  An 
empirical absorption correction was carried out using SADABS [96].  The structure was 
solved with the direct methods and refined by a full matrix least square methods based on 
F
2
, using the structure determination package SHELXTL [97] based on SHELX 97 [98].  
Graphics were generated using ORTEP-3 [99].  With the help of riding model Hydrogen 
atoms other than those of the water molecules, were included at calculated positions. 






For complex 1B, the hydrogen atoms of the water molecules could not be located.  For 
complex 9B, one ligand carbon atom (C3) presents a two-site (C3A, C3B) disorder, the 
main component was refined to a site occupancy of 0.66(2).  Hydrogen atoms of the 
water molecule were located on a Fourier Difference map and refined isotropically.  
Table 2 depicts the crystallographic data, while Table 7 shows the selected bond lengths 






















Table 2.  Crystal And Structure Refinement Data For Compounds 1B & 9B 
 
1B 2B 
CCDC deposit no. 902467 857990 
Empirical formula  C16 H36 Cl2 N8 O2 Pt S4 C16 H34 Cl2 N8 O Pt S4 
Formula weight  766.76 748.74 
Temperature (K) 296(2) 301(2) 
Wavelength (Å) 0.71073 0.71073 
Crystal system Triclinic Monoclinic 
Space group  P-1 P21/c 
Unit cell dimensions 
  a (Å) 9.011(2) 8.5945(4) 
b (Å) 9.424(2) 14.2550(7) 
c (Å) 9.627(2) 23.345(1) 
 92.275(4) 90 
 99.333(4) 91.383(1) 
 116.185(3) 90 
Volume (Å
3
) 718.2(3) 2859.2(2) 
Z 1 4 
Calc.  density  (g.cm
-3
) 1.773 1.739 
Absorp.  coefficient  (mm
-1
) 5.39 5.411 
F(000) 380 1480 
Crystal size (mm) 0.27 x 0.22 x 0.15 0.58 x 0.17 x 0.15 
 range (
o
) 2.16 - 28.37 1.67 - 28.29 
Limiting indices -12 ≤ h ≤ 11   -11 ≤ h ≤ 11   
 
-12 ≤ k ≤ 12   -19 ≤ k ≤ 19   
 
-12 ≤ l ≤ 12   -31 ≤ l ≤ 31   
Max and min transmission Tmin= 0.3239, Tmax= 0.4986     Tmin= 0.1454, Tmax= 0.4974     
Data/restraints/parameters 3552 / 0 / 153 7104 / 44 / 308 
Goodness-of-fit on F
2
 1.041 1.040 
Final R indices [I >2s(I)] R1 = 0.0255, wR2 = 0.0543  R1 = 0.0236, wR2 = 0.0538  
R indices (all data) R1 = 0.0259, wR2 = 0.0545    R1 = 0.0327, wR2 = 0.0570    
Largest diff.  Peak and hole (e Å
-3







4 CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Synthesis of the complexes 
Based on the available analytical data, two types of complexes were synthesized. These 
are molecular compounds with a general formula [PtL2Cl2], and ionic species with a 
formula of [PtL4]Cl2.  The direct addition of a solution of potassium 
tetrachloroplatinate(II) K2PtCl4 (0.500 mmol) to hot aqueous solution of the thione ligand 
(9) (2.00 mmol) resulted in the formation of a yellow clear solution.  After the mixture 
was refluxed for 4 hours, the solution was left at room temperature and yellow crystals 
suitable for X-ray structure determination were recovered after solvent evaporation.  The 
other thiones immediately formed turbid mixtures when treated with K2PtCl4, which 
turned to clear solutions after reflux.   A yellow crystalline product suitable for X-ray 
structure determination formed after solvent evaporation in case of ligand (1).  When 
aqueous solutions of K2PtCl4 have been treated with thione ligands in a molar ratio of 1 : 
2, immediately precipitates were formed.  The resulted complexes are expected to have 
trans configuration based on the  stereochemical regards and the stronger trans effect of 
the thione ligands [100, 101].  Unlike the free thione ligands which are soluble in most 
polar solvents, complexes 1A and 2A are only soluble in DMF, DMSO and slightly 
soluble in chloroform.  The complexes formed are air-stable and therefore they could be 




4.2 Characterization of complexes 
The most important IR frequencies are quoted in Table 3.  As mentioned by many 
authors, the assignment of the thioamides absorptions of the free thiones and their related 
compounds is not straightforward [100, 102, 103]; this is due to the strong coupling 
between thiocarbonyl absorption with various bond absorptions in the fingerprint region 
in the IR spectrum [100, 102, 103].  Nevertheless, a strong and broad band in the range of 
1400-1600 cm
−1
 appears for all the thione ligands and their related complexes.  Based on 
available literature data, this band must be due to (N–H) deformation and (N–C–N) 
antisymmetric stretching.  This band is often split and significantly shifted to higher 
frequency upon complexation; this is an indication of the increase in the double bond 
character of the C–N bond due to the coordination through sulfur [100, 103, 104].  The 
band observed in the range of the 3220–3300 cm
−1
 region for most of the thione ligands 
and their related complexes is directly assigned for N–H stretching vibrations [100, 102, 
103, 105].  This band is shifted to higher frequencies for most of the platimun(II) 
complexes due to the increase in double bond character which also supports the idea of 
coordination through sulfur and indicates that in the solid state the thione form 
dominates.  The assignment of thiocarbonyl frequencies is the most difficult part in the 
IR spectra because it strongly couples with other bonds within the molecule and gives 
rise to many bands in the fingerprint region.  Many absorption bands in the IR spectrum 
of  the free thiones, for instance MeImt: 1236, 1111, 957, 670, 637, 612, and  516 cm
−1
, 
have shifted to lower wavenumber with no more than 21 cm
−1
 in its related compounds, 




pattern of this shift has been noticed for most of the platinum complexes which indicate 
the presence of the platinum - sulfur bond. 
The main Raman absorption bands of the complexes are summarized in Table 4, a strong 
and broad band in the range of 315−337 cm
−1 
is observed for all the complexes with 
general formula [PtCl2L2] which has been assigned to Pt−Cl vibration [103, 106].  This 
band did not appear in the ionic compounds with the general formula [PtL4]Cl2.  It may 
associate with a second vibration mode or in some complexes appears as shoulder that 
could be assigned to the presence of a cis configuration[103].   
Finally, it seems appropriate to obtain more definitive evidence of the coordination site 
through another diagnostic tool, such as, NMR spectroscopy as well as X-ray 





Table 3.  Selected IR absorption (cm
−1
) the thiones and their Platinum(II) complexes 
MeImt 3195mb 1527sh 1511s 1479s 1445sh 1296sb 1236m 1111m 957m 670m 637m 612m 516s     
1A 3282wb 1546s 1506s 1476m 1463m 1327s 1292s 1222w 1110m 955w 634w 591w 502w     
1B 3498w 3430w 3172wb 1541s 1512s 1470m 1324m 1293m 1109m 956w 636w 614w 567w 503w   
                                
EtImt 3188wb 1510s 1480m 1465m 1450m 1321m 1256s 1132m 943w 790w 668w 616w 514w     
2A 3266mb 1531s 1506s 1475s 1317m 1278m 1254m 1122m 945w 787w 623w 500w       
2B 3447wb 3080wb   1533s 1509s 1471s 1316m 1281m 1249m 1119m 948w 791w 624w 499w   
                                
PrImt 3206mb 1516sb 1479m 1460m 1308m 1241m 1195sh 1122 1035w 963w 674w 616s 515vs     
3A 3343wb 3201mb 1533s 1504s 1473m 1318m 1242m 1126w 1028w 959w 669w 616w 504w     
3B 3400wb 3202m 1533s 1502s 1475m 1437m 1315m 1281m 1244m 1026w 958w 662w 607mb 507w   
                                
i-PrImt 3209mb 1510s 1474s 1450s 1334m 1268s 1127w 1063s 964m 627sh 609s 526m       
4A 3267wb 1529s 1499s 1472s 1326m 1285s 1127w 1066s 958w 608m 521w         
4B 3313mb 1529s 1498s 1473s 1368m 1325m 1287m 1256sh 1128w 1065s 958m 607m 525w     
                                
zain                




Me2Imt 3445wb 1511mb 1484m 1446m 1396m 1325m 1286m 1220m 1134w 1113m 1067m 960w 641m 626m 507 
5A 3447wb 1544s 1501m 1471w 1404w 1328s 1288m 1222w 1119m 954w 620m 491w       
Et2Imt 3452wb 1504sb 1465s 1445s 1429s 1331m 1273sb 1195m 1124m 1067m 977w 783s 631sb 510s   
6A 3461wb 1573vs 1457m 1334mb 1291s 1210w 1105w 958w 790w 619w           
                                
i-Pr2Imt 3453wb 1577w 1521m 1485m 1437m 1394m 1330s 1269s 1189m 1125s 1072s 1001m 640m 618w 590m 
7A 3448wb 1636w 1518s 1486m 145m5 1366w 1324m 1281m 1172w 1128w 1076w 1026w 623w 602w   
                                
EtMeImt 1506mb 1463mb 1393w 1334m 1270m 1205w 1120m 1085w 966w 779w 635s 620s 510vs     
8A 1580w 1542s 1503m 1461w 1330m 1279s 1202w 1128w 1099w 961w 797w 669w 633w 613w 494vw 
                                
Diaz 3210wb 1568sb 1479w 1430m 1361m 1317m 1206mb 1066m 970m 812m 769m 644m 567m 516m   
9A 3209wb 1573sh 1550s 1469w 1421m 1365s 1315s 1198s 1070w 973w 810m 739w 599m 523w   
9B 3238mb 1596s 1544s 1473s 1416m 1360s 1312s 1199s 1073w 973w 814m 753wb 617w 520w   
                                
EtDiaz 3220mb 3024w 1539sb 1476w 1460w 1443m 1376m 1332m 1308m 1260m 1128m 1106m 705m 637m 509w 
10A 3445wb 3155wb 1626s 1574s 1510sb 1437m 1374m 1315m 1257m 1129m 1105w 972w 690 564w 445w 
10B 3408mb 3248mb 1580sb 1522m 1508m 1440m 1374m 1316m 1258m 1127m 1105w 971w 693w 565w 444w 




Diap 3220wb 1564sb 1535sb 1453m 1355m 1324m 1213sb 922w 814m 757m 644m 526m       
11A 3338m 3208mb 1639w 1544sb 1438mb 1354m 1325m 1212vs 914w 809w 764 727 634m 521w   
11B 3202mb 1586m 1551sb 1456m 1439m 1351m 1324m 1222sb 919w 810m 760m 733w 669w 644m 520w 




Table 4.  Selected Raman absorption (cm
−1
)  frequencies for some of the 
platinum(II) complexes 
 






C NMR chemical shifts of the free thione ligands and their complexes were 




C resonances were studied in DMSO.  Complexes 2A, 9B, 11A and 11B have been 
dissolved in 50:50 (v/v) mixture of CDCl3 and DMSO.  The spectroscopic data are given 
in Table 5.  In 
1
H NMR spectrum, because these complexes are highly symmetrical 
arranged with respect to the coordination core; their coordinated ligands showed similar 
chemical shifts.  The N–H protons of the coordinated thiones are shifted toward high 
frequency with respect to the free thiones.  This large deshielding of the N–H protons is 
an indication of the increase in the double bond character of the C–N bond upon 
coordination to Pt(II) which is consistent with the coordination of thiourea or its 
derivatives to the metal [90, 103, 107].  The appearance of a N–H signal is an indication 
of coordinating to Pt(II) via the thione group.  On the other hand, 
13
C NMR signal for the 
thiocarbonyl carbon in the all complexes shifted upfield by 6.0 to 11.0 ppm with respect 






6A 337sb  320sb 
8A 333m  320sb 
9A 327vs 
10A  323mb  




to the reduction in C=S bond order and increase in C–N bond order upon complexation 
[90, 103].   
For solid state 
13
C NMR spectra, Table 6, the complexation of Pt(II) with the thiones 
resulted in shielding of thiocarbonyl carbons in the obtained complexes by about 8 to 10 
ppm in comparison with their free thione ligands [108].  This also confirms that the 
thione form is retained in the complexes.  The diap ligand and the corresponding 
complexes showed 3 peaks in the thiocarbonyl region.  This may be attributed to the 
different conformations of the 7-membered ring. 
According to the solid state 
15
N spectra, Table 6, the nitrogens in the synthesized 
compounds  are about 5 to 8 ppm deshielded in comparison with their free ligands.  
15
N 
NMR of the complexes 9B and 11B showed three and four different environments, 
respectively, which is corroborated by the X-ray structure, where the nitrogen atoms are 
in slightly different environments.  Hence, it can be inferred that most of the complexes 
studied depict two crystallographically inequivalent complex molecules per unit cell or 
two nonequivalent ligands per complex molecule. 
The potassium tetrachloroplatinate is reported to have an axial symmetry, and the tensor 
has a very large chemical shift anisotropy of 10414 ppm [109].  The 
195
Pt NMR of 
complex 9B lies in the same range observed for other Pt(II) complexes surrounded by 
four sulfur containing ligands in square planar geometry [110, 111].  The observed low 
anisotropy in our complex may be attributed to the deviation from the perfect axial 
symmetry.  We were unable to record platinum spectra for the other complexes, 





Figure 6.  
195
Pt CPMAS spectrum of 9B at a spinning rate of 11kHz.  The isotropic 
peak is marked * 
 




C chemical shifts (ppm) of the thiones and their Pt(II)-thione 
complexes in CDCl3 
Species  N–H C–2 C–4 C–5 C–6 N–C1 N–C2 
MeImt
a





 173.67 42.44 51.93   33.51   
1B
a
 9.41 173.55 42.27 51.68   33.60   
EtImt
b
 5.67 183.02 41.56 47.85   41.23 12.02 
2A
c
 9.40 173.48 42.48 48.80   41.40 12.15 
2B 9.67 174.41 42.78 49.11   41.78 12.44 
PrImt
b
 5.88 183.72 41.38 48.63   48.63 20.44 11.18
d
 
3A 9.71 175.18 42.74 50.06   48.59 20.70 11.19
d
 





 5.63 182.51 41.48 42.85   46.90 19.32 
4A 10.02 9.64
f
 174.23 42.61 43.72   47.26 19.73 
4B 9.65 173.89 42.73 44.00   47.59 19.68 
Me2Imt - 183.56 48.31 48.31   35.14   
5A - 177.70 48.96 48.96   35.95   






 - 171.53 43.22 43.22   46.29 12.38 
i-Pr2Imt - 180.88 40.46 40.46   46.88 19.16 
7A - 174.43 40.94 40.94   48.10 19.74 
EtMeImt - 182.47 42.30 45.16   48.21 34.71
e
 11.19 





 6.75 176.81 40.59 19.30 40.59     
9A
c
 9.13 167.86 40.39 18.93 40.39     
9B
c
 9.08 167.68 40.15 18.86 40.15     
EtDiaz
b
 6.31 176.88 45.41 21.00 40.73 48.92 11.99 
10A 9.62 168.91 46.43 20.41 40.72 48.89 12.77 
10B 9.39 168.55 46.90 20.56 40.38 49.08 12.76 
Diap
b
 6.69 189.42 46.28 27.33 27.33     
11A
c
 9.09 178.03 46.25 26.42 26.42     
11B
c














































C solid NMR chemical shifts (ppm) for the ligands and their 
Pt(II) complexes 
Species N–1 C–2 C–4 C–5 C–6 N–C1 N–C2 
MeImt -275.29 -277.41
a
 180.97 40.68 50.85     34.19 
1A -271.43 171.32 44.05 52.21     34.51 
1B -269.03 -279.95
a
 173.03 43.32 52.50     35.07 32.90
b
 
Diaz -273.43 175.22 39.79 19.90 39.79     
9A -265.79 - 41.29 19.23 41.29     
9B -265.15 168.38 42.39 20.96 42.39     
  -270.26
a
 167.38 41.60 19.91 41.6     
  -274.87
a
 166.41           
EtDiaz -271.38 -274.85
a
 175.76 41.62 21.58 46.68 46.68 12.77 
10B -258.24 -270.75
a
 168.82 41.58 20.69 48.4 48.4 12.73 
    166.60           
Diap -265.55 188.22 48.62 27.80 27.80     
    186.17 45.75         
    183.08 44.50         
11A -265.77 168.20 47.24 27.20 27.20     
11B -259.12 -263.62
a
 181.70 48.47 28.38 28.38     
   180.16 45.81 23.97 23.97     
    174.79 43.35         
a 
Resonance due to nonequivalent amino groups 
b 






4.3 X-ray crystal structure 
4.3.1 Crystal structure of compound 1B 
The platinum (II) ion is located on an inversion center and bound to the S atoms of four 
N-methylimidazolidine-2-thione (MeImt) ligand molecules in a distorted square planar 
geometry.  The Pt-S bond distances are 2.3243(9) Å and 2.3263(9) Å and the S-Pt-S bond 
angle is 92.11(3)°.  These values are in agreement with those reported for the complex 
tetrakis(Imidazolidine-2-thione)-platinum(II) di-iodide [112].  The SCN2 moieties of the 
two ligand molecules are essentially planar with the following bond lengths (d(S1-C1) = 
1.705(4)Å, d(C1-N1) = 1.321(5) Å, d(C1-N2) = 1.468(5) Å) and (d(S2-C5) = 1.709(3)Å, 
d(C5-N3) = 1.313(5) Å, d(C5-N4) = 1.333(4) Å).  The N-H groups (N1-H1 and N3-H3) 
are engaged in hydrogen bonding with the chloride ions.  The ORTEP atomic labeling 
scheme is given in Figure 7. 
4.3.2 Crystal structure of compound 9B 
To the best of our knowledge, this is the first X-ray structure of a platinum complex 
based on 1,3-Diazinane-2-thione (Diaz) ligand [113].  In this compound, Pt(II) ion is 
bonded to four sulfur atoms, each belonging to a Diaz ligand in a distorted square planar 
geometry.  The Pt-S bond lengths are in the range 2.3111(8)-2.3321(8) Å while the S-Pt-
S bond angles are in the range 87.99(3)-93.67(3) °.  These values are similar to those 
found for tetrakis(thiourea-S)-platinum(II) dichloride [114] and tetrakis(1-Methyl-4-
imidazoline-2-thione)-platinum(II) dichloride dehydrate [115].  The SCN2 moieties of the 
four ligand molecules are essentially planar with the S-C and C-N bond lengths in the 




bond lengths noted for the free ligand are (d(S-C) = 1.720 Å, d(C-N) = 1.331 Å) [116].  
The significantly longer S-C bond distances, associated with shorter C-N bonds in the 
complex, are consistent with significant C-N double bond character and electron donation 
from the ligand to the metal ion.  Each of the four Diaz ligands is engaged in hydrogen 
bonding interactions with one chloride counter ion (Cl1).  This results in an umbrella type 
structure where all tetrahydropyrimidine rings are on the same side of the PtS4 mean 
plane (Figure 8).  Other hydrogen bonding interactions also take place including those 




Figure 7.  ORTEP diagram of 1B showing the atomic labeling scheme.  






Figure 8.  ORTEP diagram of 9B showing the atomic labeling scheme.  
Displacement ellipsoids are drawn at the 30% probability level.  Methylene 
hydrogen atoms have been omitted for clarity 
 
 









Table 7.  Selected bond lengths (Å) and bond angles (
o
) for compounds 1B & 9B 










Pt1-S1 2.3243(9) S1-Pt1-S2 92.11(3)  Pt1-S3 2.3111(8) S3-Pt1-S1 171.53(3) 
Pt1-S2 2.3263(9) S1-Pt1-S2
i
 87.89(3)  Pt1-S1 2.3240(8) S3-Pt1-S4 87.99(3) 
S1-C1 1.705(4)    Pt1-S4 2.3263(8) S1-Pt1-S4 88.01(3) 
S2-C5 1.709(3) N1-C1-N2 110.2(3)  Pt1-S2 2.3321(8) S3-Pt1-S2 89.25(3) 
  N3-C5-N4 110.2(3)    S1-Pt1-S2 93.67(3) 
N1-C1 1.321(5)      S4-Pt1-S2 171.72(3) 
N2-C1 1.330(4)        
N3-C5 1.313(5)        
N4-C5 1.333(4)        















5 CHAPTER 5 
CONCLUSION AND RECOMMENDATION 
We successfully synthesized a series of molecular compounds with a general formula 
[PtL2Cl2], and ionic species with a formula of [PtL4]Cl2, and fully characterized them 
using various analytical techniques. NMR as well as X-ray crystallography confirmed 
that the Pt(II) ion is bonded to the thione ligands through their sulfur atoms. It was 
discovered that hydrogen bonding is an important factor that affect the stability of these 
complexes. Steric effect was found to play an important role in the synthesis of these 
complexes; highly steric ligands prefer to form complexes in general formula [PtL2Cl2],  
while the less steric ligands could form the two formulas. 
For the application of the synthesized complexes, we recommend that more work be done 
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